title: Is sibutramine more than a slim hope?
abstract: Sibutramine (Reductil-Abbott Laboratories), an orally active monoamine re-uptake inhibitor, is marketed in the UK for treating overweight adults. The company claims that it "helps obese patients control their eating". Is the drug worth prescribing?
mesh_terms: D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003503:Cyclobutanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D004038:Diet, Reducing; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine